Abbott Laboratories ABT

Revenue Intelligence Report • 33 quarters of SEC filing data • Updated 2026-03-06

Abbott Laboratories demonstrates strong revenue generation capabilities, with $1 of R&D spending yielding $2.76 in long-term revenue and $1 of SG&A spending producing $4.33. The company's latest quarterly revenue reached $11.46 billion, reflecting a solid performance amid a 3.8% MAPE model accuracy. With a fiscal year forecast projecting $47 billion in revenue, representing a 6.7% year-over-year growth, Abbott is well-positioned for continued financial success. Investors can expect robust returns driven by strategic investments in research and operational efficiency.

Next FY Revenue

$47.30B

+6.7% YoY

R&D Multiplier

$2.76 per $1

SG&A Multiplier

$4.33 per $1

Model Accuracy

3.8% MAPE

Holdout validation: The model predicted $12B vs the actual $11B — an error of 1.2%.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$12B	$11B	$11B – $13B	+5.7%	✓ In range
Q2 2026	$12B		$10B – $13B	+12.0%
Q3 2026	$12B		$10B – $13B	+5.0%
Q4 2026	$12B		$10B – $14B	+4.7%
Q1 2027	$12B		$10B – $14B	+5.5%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch